Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
ID: 357172Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $100K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357172

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PA-25-246.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced the "Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)." This program aims to support innovative research projects focused on Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), specifically targeting early-stage and diverse researchers who have not previously received significant NIH funding in this field. The initiative is designed to generate pilot data that can lead to larger funding applications, thereby enhancing research capabilities and workforce diversity in biomedical research. Grants of up to $100,000 per year for two years are available, with the application process opening on January 16, 2025, and the closing date set for March 16, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PA-25-246-Full-Announcement.html
    PA-25-246.html
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has issued a funding opportunity titled "Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)." This program aims to encourage early-stage and diverse researchers to undertake innovative studies focused on Alzheimer's disease (AD) and associated dementias (ADRD). Grants of up to $100,000 per year for two years are available to support projects addressing various topics related to AD/ADRD, including prevention, diagnosis, treatment, and care. The initiative specifically targets individuals who have not previously competed for significant NIH awards in AD/ADRD research and aims to generate pilot data that can lead to larger funding applications. The application process opens on January 16, 2025, with subsequent deadlines following a structured review cycle. Eligible applicants include academic institutions, nonprofits, and government entities, with a strong encouragement for applications from underrepresented groups. The program underscores the NIH's commitment to enhancing research capabilities in AD/ADRD and addressing workforce diversity in biomedical research.
    Similar Opportunities
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD) through the R01 Clinical Trial Optional grant program. This initiative aims to support innovative research that addresses significant biomedical, social, and behavioral aspects of aging, with a focus on inclusivity and diversity in participant recruitment. Given the projected rise in expenditures for AD-related care, which could exceed $1 trillion by 2050, this funding is critical for advancing understanding and treatment of dementia-related challenges. Interested applicants can find more information and submission guidelines at the NIH grants website, with applications due by November 5, 2027, and no specific budget limits outlined.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NIA Expanding Research in Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD) Summer Research Education Program (R25). This program aims to support the development and implementation of summer research education experiences for high school students, undergraduates, and science teachers, particularly those from underrepresented backgrounds, to enhance the research workforce in the AD/ADRD field. The initiative is crucial for providing early exposure to AD/ADRD research and encouraging participants to pursue careers in biomedical and behavioral sciences. Up to five awards of $200,000 in direct costs per year for up to five years are anticipated, with applications due by May 26, 2027. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)." This initiative aims to develop a diverse, interdisciplinary workforce capable of conducting translational research on AD and ADRD, supporting training programs for predoctoral and postdoctoral researchers with varied educational backgrounds. The program emphasizes the importance of interdisciplinary collaboration and aims to enhance understanding and treatment of aging-related health issues. NIH plans to award an estimated 3-5 grants annually over the next three years, with a total budget of $2.7 million, and applications are due by September 25, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIA Predoctoral Fellowship Award to Promote Broad Participation in Translational Research for AD/ADRD (F31 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIA Predoctoral Fellowship Award aimed at promoting diversity in the translational research workforce focused on Alzheimer's disease and related dementias (AD/ADRD). This grant supports promising predoctoral candidates from diverse backgrounds in acquiring essential translational research skills, with an emphasis on interdisciplinary approaches to AD/ADRD research, although independent clinical trials are not permitted. The initiative is crucial for fostering a diverse pool of trained scientists capable of addressing the biomedical and social challenges associated with aging and dementia. The total funding available is $335,000 for six anticipated awards, with key application deadlines starting on March 8, 2025, and the final close date set for December 8, 2027. For more information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-333.html.
    NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25 Independent Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25), aimed at enhancing training for a skilled workforce in Alzheimer's Disease (AD) and Alzheimer's Disease and Related Dementias (ADRD). This program seeks to support educational activities that provide intensive research experiences for recent baccalaureates, particularly those from underrepresented backgrounds, to prepare them for advanced degree programs or research careers in AD/ADRD. The NIH plans to commit $2,000,000 in FY 2027 and FY 2028 to fund up to five new awards annually, with a maximum project period of five years and direct costs of up to $400,000 per year. Interested applicants can find more information and application details at the provided link and should direct inquiries to grantsinfo@nih.gov, with applications due by May 26, 2027.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" aimed at developing a diverse and interdisciplinary workforce for translational research in this critical health area. The initiative invites eligible institutions to create training programs for predoctoral and postdoctoral researchers, focusing on enhancing skills in data science, disease biology, and drug discovery, while not permitting independent clinical trials. With an anticipated budget of approximately $2.7 million annually for 3-5 awards over fiscal years 2025-2027, applications are due by September 25, 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.